Zealand Pharma's Short Bowel Syndrome Treatment Wins EU Approval

10:51 AM EST, 11/13/2026 (MT Newswires) -- Zealand Pharma's (ZEAL.CO) Zeydovio received European Commission marketing authorization for the treatment of adults with short bowel syndrome, a rare, chronic and severe disease associated with reduced or complete loss of intestinal function, according to a Friday filing. The approval is backed by the biotechnology company's phase 3 Ease-1 trial, in which the twice-weekly glepaglutide led to a statistically significant greater reduction in parenteral support requirements than placebo among patients with short bowel syndrome and intestinal failure. The approval covers all European Union member states, Iceland, Liechtenstein and Norway, making Zeydovio the first and only ready-to-use GLP-2 therapy to receive regulatory approval